LIVIVO - Search results -

Search results

Result 1 - 10 of total 20

Search options

Article ; Online: Impact of heat stress on thermal balance, hydration and cortical response among outdoor workers in hot environment - an exploratory report from North East India.

Srinivasan, Krishnan / Boulton, Chaki G / Bhattacharjee, Manasi / Sinha, Abhishek / Loganathan, Sundareswaran / Seethy, Ashikh / Alam, Saklain M / Hanse, Benzamin

Journal of basic and clinical physiology and pharmacology

2024 Volume 35, Issue 1-2, Page(s) 79–84

Abstract: Objective: The objective of our study was to assess the impact of heat stress on hydration and cognition among outdoor workers in hot environment.: Methods: Area heat stress assessments were measured using Quest Temp WBGT monitor. Sweat rate for ... ...

Abstract	Objective: The objective of our study was to assess the impact of heat stress on hydration and cognition among outdoor workers in hot environment. Methods: Area heat stress assessments were measured using Quest Temp WBGT monitor. Sweat rate for dehydration and reaction time for acute cognitive processing were recorded using standard procedures. Results: Heat stress measurements ranged from 23.8 °C - 42 °C. More than 50 % of the workers had high sweat rate (>1.2 L/h) when exposed to high environmental temperatures. Positive correlation was obtained between WBGT, sweat rate and reaction time which indicates that hyperthermia has an impact on neural network processing. Heart rate and reaction time also increased with rise in WBGT and heavy physical activity. Conclusions: There was impairment of cognitive functions (reaction time) under heat stress conditions. Hence, reaction time can be used to assess the short-term impact of heat stress on neural modulation and will help to plan effective intervention strategies to reduce morbidity and mortality among workers.
MeSH term(s)	Humans ; Hot Temperature ; Occupational Exposure/adverse effects ; Temperature ; Heat-Shock Response ; Heat Stress Disorders ; India
Language	English
Publishing date	2024-03-13
Publishing country	Germany
Document type	Journal Article
ZDB-ID	1071737-7
ISSN	2191-0286 ; 0792-6855 ; 0334-1534
ISSN (online)	2191-0286
ISSN	0792-6855 ; 0334-1534
DOI	10.1515/jbcpp-2024-0003
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3207: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article: Case report: Characterization of a rare pathogenic variant associated with loss of COL3A1 expression in vascular Ehlers Danlos syndrome.

Manhas, Janvie / Lohani, Lov Raj / Seethy, Ashikh / Kumar, Uma / Gamanagatti, Shivanand / Sen, Sudip

Frontiers in cardiovascular medicine

2022 Volume 9, Page(s) 939013

Abstract: The vascular subtype of Ehlers Danlos Syndrome (vEDS) is a rare connective tissue disorder characterized by spontaneous arterial, bowel or organ rupture. The diagnosis of vEDS is established in a proband by identification of a heterozygous pathogenic ... ...

Abstract	The vascular subtype of Ehlers Danlos Syndrome (vEDS) is a rare connective tissue disorder characterized by spontaneous arterial, bowel or organ rupture. The diagnosis of vEDS is established in a proband by identification of a heterozygous pathogenic variant in the alpha-1 gene of type III collagen (
Language	English
Publishing date	2022-10-11
Publishing country	Switzerland
Document type	Case Reports
ZDB-ID	2781496-8
ISSN	2297-055X
ISSN	2297-055X
DOI	10.3389/fcvm.2022.939013
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: TETology: Epigenetic Mastermind in Action

Seethy, Ashikh / Pethusamy, Karthikeyan / Chattopadhyay, Indranil / Sah, Ramkishor / Chopra, Anita / Dhar, Ruby / Karmakar, Subhradip

Applied biochemistry and biotechnology. 2021 June, v. 193, no. 6

2021

Abstract: Cytosine methylation is a well-explored epigenetic modification mediated by DNA methyltransferases (DNMTs) which are considered “methylation writers”; cytosine methylation is a reversible process. The process of removal of methyl groups from DNA remained ...

Abstract	Cytosine methylation is a well-explored epigenetic modification mediated by DNA methyltransferases (DNMTs) which are considered “methylation writers”; cytosine methylation is a reversible process. The process of removal of methyl groups from DNA remained unelucidated until the discovery of ten-eleven translocation (TET) proteins which are now considered “methylation editors.” TET proteins are a family of Fe(II) and alpha-ketoglutarate-dependent 5-methyl cytosine dioxygenases—they convert 5-methyl cytosine to 5-hydroxymethyl cytosine, and to further oxidized derivatives. In humans, there are three TET paralogs with tissue-specific expression, namely TET1, TET2, and TET3. Among the TETs, TET2 is highly expressed in hematopoietic stem cells where it plays a pleiotropic role. The paralogs also differ in their structure and DNA binding. TET2 lacks the CXXC domain which mediates DNA binding in the other paralogs; thus, TET2 requires interactions with other proteins containing DNA-binding domains for effectively binding to DNA to bring about the catalysis. In addition to its role as methylation editor of DNA, TET2 also serves as methylation editor of RNA. Thus, TET2 is involved in epigenetics as well as epitranscriptomics. TET2 mutations have been found in various malignant hematological disorders like acute myeloid leukemia, and non-malignant hematological disorders like myelodysplastic syndromes. Increasing evidence shows that TET2 plays an important role in the non-hematopoietic system as well. Hepatocellular carcinoma, gastric cancer, prostate cancer, and melanoma are some non-hematological malignancies in which a role of TET2 has been implicated. Loss of TET2 is also associated with atherosclerotic vascular lesions and endometriosis. The current review elaborates on the role of structure, catalysis, physiological functions, pathological alterations, and methods to study TET2, with specific emphasis on epigenomics and epitranscriptomics.
Keywords	5-methylcytosine ; DNA ; DNA methylation ; DNA methyltransferase ; RNA ; biotechnology ; catalytic activity ; endometriosis ; epigenetics ; hepatoma ; melanoma ; myeloid leukemia ; oxidation ; prostatic neoplasms ; stomach neoplasms
Language	English
Dates of publication	2021-06
Size	p. 1701-1726.
Publishing place	Springer US
Document type	Article
Note	NAL-AP-2-clean ; Review
ZDB-ID	392344-7
ISSN	0273-2289
ISSN	0273-2289
DOI	10.1007/s12010-021-03537-5
Database	NAL-Catalogue (AGRICOLA)

In stock of ZB MED Bonn / Germany

Z 80/718: Show issues

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: TETology: Epigenetic Mastermind in Action.

Seethy, Ashikh / Pethusamy, Karthikeyan / Chattopadhyay, Indranil / Sah, Ramkishor / Chopra, Anita / Dhar, Ruby / Karmakar, Subhradip

Applied biochemistry and biotechnology

2021 Volume 193, Issue 6, Page(s) 1701–1726

Abstract: Cytosine methylation is a well-explored epigenetic modification mediated by DNA methyltransferases (DNMTs) which are considered "methylation writers"; cytosine methylation is a reversible process. The process of removal of methyl groups from DNA remained ...

Abstract	Cytosine methylation is a well-explored epigenetic modification mediated by DNA methyltransferases (DNMTs) which are considered "methylation writers"; cytosine methylation is a reversible process. The process of removal of methyl groups from DNA remained unelucidated until the discovery of ten-eleven translocation (TET) proteins which are now considered "methylation editors." TET proteins are a family of Fe(II) and alpha-ketoglutarate-dependent 5-methyl cytosine dioxygenases-they convert 5-methyl cytosine to 5-hydroxymethyl cytosine, and to further oxidized derivatives. In humans, there are three TET paralogs with tissue-specific expression, namely TET1, TET2, and TET3. Among the TETs, TET2 is highly expressed in hematopoietic stem cells where it plays a pleiotropic role. The paralogs also differ in their structure and DNA binding. TET2 lacks the CXXC domain which mediates DNA binding in the other paralogs; thus, TET2 requires interactions with other proteins containing DNA-binding domains for effectively binding to DNA to bring about the catalysis. In addition to its role as methylation editor of DNA, TET2 also serves as methylation editor of RNA. Thus, TET2 is involved in epigenetics as well as epitranscriptomics. TET2 mutations have been found in various malignant hematological disorders like acute myeloid leukemia, and non-malignant hematological disorders like myelodysplastic syndromes. Increasing evidence shows that TET2 plays an important role in the non-hematopoietic system as well. Hepatocellular carcinoma, gastric cancer, prostate cancer, and melanoma are some non-hematological malignancies in which a role of TET2 has been implicated. Loss of TET2 is also associated with atherosclerotic vascular lesions and endometriosis. The current review elaborates on the role of structure, catalysis, physiological functions, pathological alterations, and methods to study TET2, with specific emphasis on epigenomics and epitranscriptomics.
MeSH term(s)	5-Methylcytosine/analogs & derivatives ; 5-Methylcytosine/metabolism ; Animals ; DNA Methylation ; Dioxygenases/genetics ; Dioxygenases/metabolism ; Epigenesis, Genetic ; Humans
Chemical Substances	5-hydroxymethylcytosine (1123-95-1) ; 5-Methylcytosine (6R795CQT4H) ; Dioxygenases (EC 1.13.11.-)
Language	English
Publishing date	2021-03-10
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	392344-7
ISSN	1559-0291 ; 0273-2289
ISSN (online)	1559-0291
ISSN	0273-2289
DOI	10.1007/s12010-021-03537-5
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 3053: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Alterations of the expression of TET2 and DNA 5-hmC predict poor prognosis in Myelodysplastic Neoplasms.

Seethy, Ashikh A / Pethusamy, Karthikeyan / Kushwaha, Tushar / Kumar, Gaurav / Talukdar, Joyeeta / Chaubey, Rekha / Sundaram, Udayakumar Dharmalingam / Mahapatra, Manoranjan / Saxena, Renu / Dhar, Ruby / Inampudi, Krishna K / Karmakar, Subhradip

BMC cancer

2023 Volume 23, Issue 1, Page(s) 1035

Abstract: Background: Myelodysplastic Neoplasms (MDS) are clonal stem cell disorders characterized by ineffective hematopoiesis and progression to acute myeloid leukemia, myelodysplasia-related (AML-MR). A major mechanism of pathogenesis of MDS is the aberration ... ...

Abstract	Background: Myelodysplastic Neoplasms (MDS) are clonal stem cell disorders characterized by ineffective hematopoiesis and progression to acute myeloid leukemia, myelodysplasia-related (AML-MR). A major mechanism of pathogenesis of MDS is the aberration of the epigenetic landscape of the hematopoietic stem cells and/or progenitor cells, especially DNA cytosine methylation, and demethylation. Data on TET2, the predominant DNA demethylator of the hematopoietic system, is limited, particularly in the MDS patients from India, whose biology may differ since these patients present at a relatively younger age. We studied the expression and the variants of TET2 in Indian MDS and AML-MR patients and their effects on 5-hydroxymethyl cytosine (5-hmC, a product of TET2 catalysis) and on the prognosis of MDS patients. Results: Of the 42 MDS patients, cytogenetics was available for 31 sub-categorized according to the Revised International Prognostic Scoring System (IPSS-R). Their age resembled that of the previous studies from India. Bone marrow nucleated cells (BMNCs) were also obtained from 13 patients with AML-MR, 26 patients with de-novo AML, and 11 subjects with morphologically normal bone marrow. The patients had a significantly lower TET2 expression which was more pronounced in AML-MR and the IPSS-R higher-risk MDS categories. The 5-hmC levels in higher-risk MDS and AML-MR correlated with TET2 expression, suggesting a possible mechanistic role in the loss of TET2 expression. The findings on TET2 and 5-hmC were also confirmed at the tissue level using immunohistochemistry. Pathogenic variants of TET2 were found in 7 of 24 patient samples (29%), spanning across the IPSS-R prognostic categories. One of the variants - H1778R - was found to affect local and global TET2 structure when studied using structural predictions and molecular dynamics simulations. Thus, it is plausible that some pathogenic variants in TET2 can compromise the structure of TET2 and hence in the formation of 5-hmC. Conclusions: IPSS-R higher-risk MDS categories and AML-MR showed a reduction in TET2 expression, which was not apparent in lower-risk MDS. DNA 5-hmC levels followed a similar pattern. Overall, a decreased TET2 expression and a low DNA 5-hmC level are predictors of advanced disease and adverse outcome in MDS in the population studied, i.e., MDS patients from India.
MeSH term(s)	Humans ; Myelodysplastic Syndromes/genetics ; Bone Marrow/pathology ; Prognosis ; Leukemia, Myeloid, Acute/pathology ; Cytosine ; DNA-Binding Proteins/genetics ; Dioxygenases
Chemical Substances	Cytosine (8J337D1HZY) ; TET2 protein, human (EC 1.13.11.-) ; DNA-Binding Proteins ; Dioxygenases (EC 1.13.11.-)
Language	English
Publishing date	2023-10-26
Publishing country	England
Document type	Journal Article
ZDB-ID	2041352-X
ISSN	1471-2407 ; 1471-2407
ISSN (online)	1471-2407
ISSN	1471-2407
DOI	10.1186/s12885-023-11449-2
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Loss of TET2 with reduced genomic 5-hmC is associated with adverse-risk AML.

Pethusamy, Karthikeyan / Seethy, Ashikh / Dhar, Ruby / Karmakar, Abhibroto / Chaudhary, Shilpi / Bakhshi, Sameer / Palanichamy, Jayanth Kumar / Chopra, Anita / Chauhan, Shyam S / Karmakar, Subhradip

Leukemia & lymphoma

2022 Volume 63, Issue 14, Page(s) 3426–3432

Abstract: While considerable information exists on the ten-eleven translocation 2 (TET2) mutational landscape in AML, the information ... ...

Abstract	While considerable information exists on the ten-eleven translocation 2 (TET2) mutational landscape in AML, the information on
MeSH term(s)	Humans ; Translocation, Genetic ; Mutation ; Genomics ; Leukemia, Myeloid, Acute/genetics ; RNA, Messenger/genetics ; DNA-Binding Proteins/genetics ; Dioxygenases/genetics
Chemical Substances	RNA, Messenger ; TET2 protein, human (EC 1.13.11.-) ; DNA-Binding Proteins ; Dioxygenases (EC 1.13.11.-)
Language	English
Publishing date	2022-09-27
Publishing country	United States
Document type	Journal Article
ZDB-ID	1042374-6
ISSN	1029-2403 ; 1042-8194
ISSN (online)	1029-2403
ISSN	1042-8194
DOI	10.1080/10428194.2022.2126278
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2997: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Cancer immunotherapy: Recent advances and challenges.

Dhar, Ruby / Seethy, Ashikh / Singh, Sunil / Pethusamy, Karthikeyan / Srivastava, Tryambak / Talukdar, Joyeeta / Rath, Goura Kishor / Karmakar, Subhradip

Journal of cancer research and therapeutics

2021 Volume 17, Issue 4, Page(s) 834–844

Abstract: Immunotherapy is a treatment that uses specific components of a person's immune system to fight diseases. This is usually done by stimulating or assisting one's immune system is attacking the offending agent - for instance, in the case of cancer - the ... ...

Abstract	Immunotherapy is a treatment that uses specific components of a person's immune system to fight diseases. This is usually done by stimulating or assisting one's immune system is attacking the offending agent - for instance, in the case of cancer - the target of immunotherapy will be cancer cells. Some types of immunotherapy are also called biologic therapy or biotherapy. One of the fundamental challenges that a living cell encounters are to accurately copy its genetic material to daughter cells during every single cell cycle. When this process goes haywire, genomic instability ensues, and genetic alterations ranging from nucleotide changes to chromosomal translocations and aneuploidy occur. Genomic instability arising out of DNA structural changes (indels, rearrangements, etc.,) can give rise to mutations predisposing to cancer. Cancer prevention refers to actions taken to mitigate the risk of getting cancer. The past decade has encountered an explosive rate of development of anticancer therapy ranging from standard chemotherapy to novel targeted small molecules that are nearly cancer specific, thereby reducing collateral damage. However, a new class of emerging therapy aims to train the body's defense system to fight against cancer. Termed as "cancer immunotherapy" is the new approach that has gained worldwide acceptance. It includes using antibodies that bind to and inhibit the function of proteins expressed by cancer cells or engineering and boosting the person's own T lymphocytes to target cancer. In this review, we summarized the recent advances and developments in cancer immunotherapy along with their shortcoming and challenges.
MeSH term(s)	Animals ; Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Immunotherapy/methods ; Neoplasms/drug therapy ; Neoplasms/immunology ; T-Lymphocytes/immunology
Chemical Substances	Immune Checkpoint Inhibitors
Language	English
Publishing date	2021-09-16
Publishing country	India
Document type	Journal Article ; Review
ZDB-ID	2187633-2
ISSN	1998-4138 ; 0973-1482
ISSN (online)	1998-4138
ISSN	0973-1482
DOI	10.4103/jcrt.JCRT_1241_20
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Exploring the Role of Gut Microbiome in Colon Cancer.

Chattopadhyay, Indranil / Dhar, Ruby / Pethusamy, Karthikeyan / Seethy, Ashikh / Srivastava, Tryambak / Sah, Ramkishor / Sharma, Jyoti / Karmakar, Subhradip

Applied biochemistry and biotechnology

2021 Volume 193, Issue 6, Page(s) 1780–1799

Abstract: Dysbiosis of the gut microbiome has been associated with the development of colorectal cancer (CRC). Gut microbiota is involved in the metabolic transformations of dietary components into oncometabolites and tumor-suppressive metabolites that in turn ... ...

Abstract	Dysbiosis of the gut microbiome has been associated with the development of colorectal cancer (CRC). Gut microbiota is involved in the metabolic transformations of dietary components into oncometabolites and tumor-suppressive metabolites that in turn affect CRC development. In a healthy colon, the major of microbial metabolism is saccharolytic fermentation pathways. The alpha-bug hypothesis suggested that oncogenic bacteria such as enterotoxigenic Bacteroides fragilis (ETBF) induce the development of CRC through direct interactions with colonic epithelial cells and alterations of microbiota composition at the colorectal site. Escherichia coli, E. faecalis, F. nucleatum, and Streptococcus gallolyticus showed higher abundance whereas Bifidobacterium, Clostridium, Faecalibacterium, and Roseburia showed reduced abundance in CRC patients. The alterations of gut microbiota may be used as potential therapeutic approaches to prevent or treat CRC. Probiotics such as Lactobacillus and Bifidobacterium inhibit the growth of CRC through inhibiting inflammation and angiogenesis and enhancing the function of the intestinal barrier through the secretion of short-chain fatty acids (SCFAs). Crosstalk between lifestyle, host genetics, and gut microbiota is well documented in the prevention and treatment of CRC. Future studies are required to understand the interaction between gut microbiota and host to the influence and prevention of CRC. However, a better understanding of bacterial dysbiosis in the heterogeneity of CRC tumors should also be considered. Metatranscriptomic and metaproteomic studies are considered a powerful omic tool to understand the anti-cancer properties of certain bacterial strains. The clinical benefits of probiotics in the CRC context remain to be determined. Metagenomic approaches along with metabolomics and immunology will open a new avenue for the treatment of CRC shortly. Dietary interventions may be suitable to modulate the growth of beneficial microbiota in the gut.
MeSH term(s)	Animals ; Bacteria/metabolism ; Colonic Neoplasms/blood supply ; Colonic Neoplasms/microbiology ; Colonic Neoplasms/therapy ; Gastrointestinal Microbiome ; Humans ; Neovascularization, Pathologic/microbiology ; Neovascularization, Pathologic/therapy
Language	English
Publishing date	2021-01-25
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	392344-7
ISSN	1559-0291 ; 0273-2289
ISSN (online)	1559-0291
ISSN	0273-2289
DOI	10.1007/s12010-021-03498-9
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 3053: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Effects of 469 E/K polymorphism of ICAM1 gene in ischemic stroke and its association with stroke severity and outcome

Karthikeyan Pethusamy / Ashikh A Seethy / Maheshwari Kulandhasamy / Pinki Garg / Debashish Chowdhury / Sarita Agarwal / Arun Kumar / Ruby Dhar / Subhradip Karmakar

Asian Journal of Medical Sciences, Vol 12, Iss 1, Pp 2-

2021 Volume 7

Abstract: Background: Stroke is the second leading cause of death globally and it is a major cause of long-term, physical, psychological, and social disability among the elderly. Increasing evidence shows that ischemic injury and inflammation account for its ... ...

Abstract	Background: Stroke is the second leading cause of death globally and it is a major cause of long-term, physical, psychological, and social disability among the elderly. Increasing evidence shows that ischemic injury and inflammation account for its pathogenic progression. So, we studied the association of Intercellular Adhesion Molecule 1 (ICAM1) polymorphism with ischemic stroke, stroke severity, and outcome. Aims and Objectives: To compare ICAM1 469 E/K polymorphism in ischemic stroke patients with healthy controls, and to study its association with stroke severity and outcome. Materials and Methods: Fifty patients of ischemic stroke and hundred healthy individuals were included. The stroke severity was assessed clinically and radiologically. Outcome was measured at three and six months of stroke onset. Genomic DNA was used for Allele-Specific PCR to detect ICAM1 469 E/K polymorphism. The subjects were categorized into EE, EK, and KK genotypes. Results: The odds of EK genotype to develop stroke was 0.41 (95 % CI; 0.17 - 0.92) (p = 0.07) and of KK genotype was 0.41 (95 % CI; 0.11 - 0.87) (p = 0.04) compared to EE genotype. Subjects with ICAM1K allele had significantly reduced risk of stroke compared with those with E allele. (RR: 0.55; 95% CI: 0.35-0.87) (p=0.03). Conclusion: Subjects with ICAM1K allele had significantly reduced the risk of developing stroke. 469 E/K polymorphism of the ICAM1 gene does not significantly affect stroke severity, mortality, and outcome.
Keywords	ischemic stroke ; intercellular adhesion molecule-1 ; polymorphism ; polymerase chain reaction ; Medicine ; R
Subject code	590
Language	English
Publishing date	2021-01-01T00:00:00Z
Publisher	Manipal College of Medical Sciences, Pokhara
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Potential SARS-CoV-2 interactions with proteins involved in trophoblast functions - An in-silico study.

Seethy, Ashikh A / Singh, Sunil / Mukherjee, Indrani / Pethusamy, Karthikeyan / Purkayastha, Kakali / Sharma, Jai Bhagwan / Sharma, Radhey S / Dhar, Ruby / Karmakar, Subhradip

Placenta

2020 Volume 103, Page(s) 141–151

Abstract: Background: Though a large number of pregnant females have been affected by COVID-19, there is a dearth of information on the effects of SARS-CoV-2 infection on trophoblast function. We explored in silico, the potential interactions between SARS-CoV-2 ... ...

Abstract	Background: Though a large number of pregnant females have been affected by COVID-19, there is a dearth of information on the effects of SARS-CoV-2 infection on trophoblast function. We explored in silico, the potential interactions between SARS-CoV-2 proteins and proteins involved in the key functions of placenta. Methods: Human proteins interacting with SARS-CoV-2 proteins were identified by Gordon et al. (2020). Genes that are upregulated in trophoblast sub-types and stages were obtained by gene-expression data from NCBI-GEO and by text-mining. Genes altered in pathological states like pre-eclampsia and gestational diabetes mellitus were also identified. Genes crucial in placental functions thus identified were compared to the SARS-CoV-2 interactome for overlaps. Proteins recurring across multiple study scenarios were analyzed using text mining and network analysis for their biological functions. Results: The entry receptors for SARS-CoV-2 - ACE2 and TMPRSS2 are expressed in placenta. Other proteins that interact with SARS-CoV-2 like LOX, Fibulins-2 and 5, NUP98, GDF15, RBX1, CUL3, HMOX1, PLAT, MFGE8, and MRPs are vital in placental functions like trophoblast invasion and migration, syncytium formation, differentiation, and implantation. TLE3, expressed across first trimester placental tissues and cell lines, is involved in formation of placental vasculature, and is important in SARS-CoV (2003) budding and exit from the cells by COPI vesicles. Conclusion: SARS-CoV-2 can potentially interact with proteins having crucial roles in the placental function. Whether these potential interactions identified in silico have effects on trophoblast functions in biological settings needs to be addressed by further in vitro and clinical studies.
MeSH term(s)	COVID-19/metabolism ; COVID-19/pathology ; Computational Biology ; Computer Simulation ; Datasets as Topic ; Female ; HEK293 Cells ; Humans ; Placenta/metabolism ; Placenta/physiology ; Placenta/virology ; Pregnancy ; Pregnancy Complications, Infectious/metabolism ; Pregnancy Complications, Infectious/pathology ; Pregnancy Proteins/metabolism ; Pregnancy Trimester, First/metabolism ; Protein Binding ; Protein Interaction Maps ; Proteomics/methods ; SARS-CoV-2/metabolism ; Trophoblasts/metabolism ; Trophoblasts/physiology ; Trophoblasts/virology ; Up-Regulation
Chemical Substances	Pregnancy Proteins
Keywords	covid19
Language	English
Publishing date	2020-10-22
Publishing country	Netherlands
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	603951-0
ISSN	1532-3102 ; 0143-4004
ISSN (online)	1532-3102
ISSN	0143-4004
DOI	10.1016/j.placenta.2020.10.027
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1578: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Bonn / Germany

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito